BACKGROUND: Despite diagnostic and therapeutic advances in head and neck cancer, the 5-year survival of patients with laryngeal cancer has not improved in the last 30 years. Several recent studies indicate that specific targets for immunotherapeutic approaches can be useful in the control of cancer. There is considerable interest in the expression of cancer testis antigens in human cancers since they may serve as the basis for an immunologic approach to therapy. METHODS: We evaluated by immunohistochemical analysis the expression of cancer testis antigens MAGE-A4 (57B), MAGE-C1 (CT7-33), MAGE-A1 (MA454), MAGE-A3 (M3H67), MAGE-C2 (CT10.5), NY-ESO-1 (E978), and GAGE (GAGE) in squamous cell carcinoma (SCC) of the larynx. RESULTS: A total of 63 cases (57 men and 6 women) of laryngeal SCC were available for this study. The findings were correlated with the clinical course and laboratory data. Expression of at least 1 cancer testis antigen was detected in 42 of 63 of the laryngeal SCCs (67%). In 34 of 42 of the positive cases (81%) there was simultaneous expression of ≥2 cancer testis antigens. There was significant correlation between antigen expression and advanced tumor stage (stage III/IV) in cases with reactivity to only 1 antibody (p = .01) as well as in the cases with reactivity to ≥2 primary antibodies (≥2 mAbs, p = .04). There was no association between survival and expression of any of the analyzed antigens. CONCLUSIONS: We find a high incidence of cancer testis antigen expression in SCCs of the larynx, which was correlated with advanced clinical stage. Our data indicate that cancer testis antigens could be valuable vaccine targets in laryngeal tumors, especially in those with a worse prognosis.
BACKGROUND: Despite diagnostic and therapeutic advances in head and neck cancer, the 5-year survival of patients with laryngeal cancer has not improved in the last 30 years. Several recent studies indicate that specific targets for immunotherapeutic approaches can be useful in the control of cancer. There is considerable interest in the expression of cancer testis antigens in humancancers since they may serve as the basis for an immunologic approach to therapy. METHODS: We evaluated by immunohistochemical analysis the expression of cancer testis antigens MAGE-A4 (57B), MAGE-C1 (CT7-33), MAGE-A1 (MA454), MAGE-A3 (M3H67), MAGE-C2 (CT10.5), NY-ESO-1 (E978), and GAGE (GAGE) in squamous cell carcinoma (SCC) of the larynx. RESULTS: A total of 63 cases (57 men and 6 women) of laryngeal SCC were available for this study. The findings were correlated with the clinical course and laboratory data. Expression of at least 1 cancer testis antigen was detected in 42 of 63 of the laryngeal SCCs (67%). In 34 of 42 of the positive cases (81%) there was simultaneous expression of ≥2 cancer testis antigens. There was significant correlation between antigen expression and advanced tumor stage (stage III/IV) in cases with reactivity to only 1 antibody (p = .01) as well as in the cases with reactivity to ≥2 primary antibodies (≥2 mAbs, p = .04). There was no association between survival and expression of any of the analyzed antigens. CONCLUSIONS: We find a high incidence of cancer testis antigen expression in SCCs of the larynx, which was correlated with advanced clinical stage. Our data indicate that cancer testis antigens could be valuable vaccine targets in laryngeal tumors, especially in those with a worse prognosis.
Authors: Johannes A Veit; Daniela Heine; Julia Thierauf; Jochen Lennerz; Subasch Shetty; Patrick J Schuler; Theresa Whiteside; Dirk Beutner; Moritz Meyer; Inga Grünewald; Gerd Ritter; Sacha Gnjatic; Andrew G Sikora; Thomas K Hoffmann; Simon Laban Journal: Head Neck Date: 2016-02-13 Impact factor: 3.147
Authors: Rachel E Beard; Daniel Abate-Daga; Shannon F Rosati; Zhili Zheng; John R Wunderlich; Steven A Rosenberg; Richard A Morgan Journal: Clin Cancer Res Date: 2013-09-10 Impact factor: 12.531
Authors: Dan P Zandberg; Sandra Rollins; Olga Goloubeva; Robert E Morales; Ming Tan; Rodney Taylor; Jeffrey S Wolf; Lisa M Schumaker; Kevin J Cullen; Ann Zimrin; Robert Ord; Joshua E Lubek; Mohan Suntharalingam; John C Papadimitriou; Dean Mann; Scott E Strome; Martin J Edelman Journal: Cancer Immunol Immunother Date: 2014-12-24 Impact factor: 6.968
Authors: Seth M Pollack; Yonqing Li; Megan J Blaisdell; Erik A Farrar; Jeffrey Chou; Benjamin L Hoch; Elizabeth T Loggers; Eve Rodler; Janet F Eary; Ernest U Conrad; Robin L Jones; Cassian Yee Journal: PLoS One Date: 2012-02-27 Impact factor: 3.240
Authors: Simon Laban; Gregor Giebel; Niklas Klümper; Andreas Schröck; Johannes Doescher; Giulio Spagnoli; Julia Thierauf; Marie-Nicole Theodoraki; Romain Remark; Sacha Gnjatic; Rosemarie Krupar; Andrew G Sikora; Geert Litjens; Niels Grabe; Glen Kristiansen; Friedrich Bootz; Patrick J Schuler; Cornelia Brunner; Johannes Brägelmann; Thomas K Hoffmann; Sven Perner Journal: Oncotarget Date: 2017-02-28
Authors: Paul Zajac; Elke Schultz-Thater; Luigi Tornillo; Charlotte Sadowski; Emanuele Trella; Chantal Mengus; Giandomenica Iezzi; Giulio C Spagnoli Journal: Front Med (Lausanne) Date: 2017-03-08